Verrica Pharmaceuticals (VRCA) Q4 2024 earnings summary

Executive summary

• Initiated a turnaround in Q4 2024 with leadership changes, a $42 million capital raise, and a focused commercialization strategy for YCANTH, targeting cost reduction and operational efficiency.

• Achieved 12.3% sequential growth in YCANTH dispensed applicator units in Q4 2024, with expanded access through new configurations and pharmacy partnerships.

• Advanced late-stage pipeline programs, including YCANTH for common warts and VP-315 for basal cell carcinoma, with VP-315 showing a 97% objective response rate in phase II.

• Restructured commercial operations, reducing expenses and optimizing field force.

• Strengthened financial position with a $42 million equity raise and a waiver of going concern covenant from OrbiMed.

Financial highlights

• Q4 2024 revenue was $0.3 million, primarily from YCANTH; full year 2024 revenue reached $7.6 million, up from $5.1 million in 2023.

• Gross product margin for 2024 was 72%; cost of product revenue included $0.9 million in obsolete inventory costs.

• Research and development expenses for 2024 were $11.8 million, down from $20.3 million in 2023.

• Selling, general, and administrative expenses for 2024 were $58.8 million, up from $47.3 million in 2023, reflecting commercial ramp-up.

• GAAP net loss for 2024 was $76.8 million ($1.48/share); non-GAAP net loss was $64.6 million ($1.25/share).

• Cash and cash equivalents as of December 31, 2024, were $46.3 million.

Outlook and guidance

• Expect continued growth in YCANTH demand and further reflection of commercial strategy in 2025 results.

• No formal revenue guidance provided; consensus for 2025 is $15 million, with management remaining cautiously optimistic.

• Sufficient cash runway contingent on milestone payments and warrant exercises; prudent cash management ongoing.

• Targeting cash positive monthly operating results by end of 2025.

• Anticipates $8 million milestone payment from Torii upon Phase 3 trial initiation for common warts, and potential proceeds from Series A warrant exercises.